Facebook
Twitter
LinkedIn
ForwardUpdate on the Management of Parkinson’s Disease
Learn about modern treatments for Parkinson’s disease — from Levodopa, widely considered the gold standard of care, to more recent interventions — from Bruno V. Gallo, M.D.
Original Release Date: February 2019
Review Date: January 2022
Target Audience
Adult and Pediatric Neurologists, Neurosurgeons, Stroke Neurologists, Neuroradiologists, Diagnostic Radiologists, Critical Care Physicians, Neurointensivists, Emergency Medicine Physicians, Internal Medicine Physicians, Interventional Neuroradiologists, Family Physicians, General Internists, Neuropsychologists, Rehabilitation and Pain Management Specialists, as well as other specialists interested in the field of neuroscience.
Learning Objectives
- Explain the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease symptoms.
- Examine advances in the development and clinical testing of compounds that promise to offer disease modification in already-manifested Parkinson’s disease.
Bruno V. Gallo, M.D.
Director of the Parkinson’s and Neuromodulation Center
Baptist Health Neuroscience Center
Neurologist, Baptist Hospital of Miami, South Miami Hospital and West Kendall Baptist Hospital
Associate Professor of Neurology
Florida International University Herbert Wertheim College of Medicine
Miami, Florida
Miami Neuroscience Symposium Planning Committee
Bruno V. Gallo, M.D., is a member of the speakers' bureau for Teva Pharmaceuticals and Sunovion Pharmaceuticals and that he serves as a consultant to Cyberonics, Inc., Teva Pharmaceuticals, St. Jude Medical, Surgimon LLC and ONS Inc. He has received fellowship and/or research grants from Medtronic International, Pfizer Pharmaceuticals, GlaxoSmithKline and St. Jude Medical and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Alberto Pinzon-Ardila, M.D., indicated that he is a member of the speakers' bureau for Sunovion and UCB Pharmaceuticals.
Kevin Abrams, M.D., indicated that he is a consultant and shareholder with Keystone Heart.
Guilherme Dabus, M.D., indicated that he is a consultant for Microvention/Terumo, Medtronic, Penumbra and Cerenovus, and on the speakers bureau for Microvention/Terumo, Medtronic and Penumbra. He is a proctor for Medtronic. Dr. Dabus is also a shareholder with Surpass Medical/Stryker, Medina/Medtronic, InNeuro Co and Three Rivers Medical.
Daniel D’Amour, M.D., Felipe De Los Rios, M.D., Karel Fuentes, M.D., Sergio Gonzalez-Arias, M.D., Ph.D., Kunal Patel, M.S., Amy K. Starosciak, Ph.D., and Jayme Strauss, R.N., MSN, have no relevant financial relationship with ineligible companies* to disclose.
Italo Linfante, M.D., indicated that he is a consultant for Medtronic, Stryker and Penumbra. He is a stockholder with InNeuro Co.
All of the relevant financial relationships listed for these individuals have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.
*Ineligible companies -- Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Your participation information will be shared with the ACCME, which will in turn report your points to ABIM. Successful completion of a course examination is required to earn ABIM MOC points.
NOTE: Maintenance of Certification (MOC) points will be automatically reported to the ABIM. Submissions are recorded in approximately 48 hours. You will receive an email when your credits have been processed.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Available Credit
- 0.50 ABIM MOC II
- 0.50 AMA PRA Category 1 Credit™
- 0.50 General certificate of attendance
NOTE: Maintenance of Certification (MOC) points will be automatically reported to the ABP. Submissions are recorded in approximately 48 hours. You will receive an email when your credits have been processed.
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
